Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $47.54 USD
Change Today +1.59 / 3.46%
Volume 3.4M
XON On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$45.54
Previous Close
$45.95
Day High
$48.99
Day Low
$45.54
52 Week High
06/22/15 - $51.44
52 Week Low
10/9/14 - $15.55
Market Cap
5.2B
Average Volume 10 Days
1.6M
EPS TTM
$-1.57
Shares Outstanding
109.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC; and strategic collaboration and licensing agreement with Merck Serono S.A. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Senior Vice President of Health Sector
Total Annual Compensation: $986.0K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

intrexon corp (XON) Key Developments

Intrexon Corporation(NYSE:XON) added to Russell 1000 Index

Intrexon Corporation has been added to Russell 1000 Index.

Intrexon Corporation(NYSE:XON) dropped from Russell 2000 Index

Intrexon Corporation will be removed from Russell 2000 Index

Intrexon Corporation and Oragenics Announce Exclusive Channel Collaboration

Intrexon Corporation and Oragenics announced a new Exclusive Channel Collaboration (ECC) to pursue development of biotherapeutics for oral mucositis (OM) and other diseases and conditions of the oral cavity, throat, and esophagus, including clinical advancement of the ActoBiotic AG013 for the treatment of OM. OM results in the painful inflammation and ulceration of the membranes lining the oral cavity, throat, and esophagus and is among the most frequently reported adverse events associated with cancer therapy affecting up to 500,000 patients annually. Under the terms of the agreement, Oragenics will have access to Intrexon's technologies and expertise to develop products for the treatment of oral mucositis or products containing genetically modified Lactococcus lactis expressing trefoil factors in the oral cavity, throat, and esophagus for a technology access fee and will reimburse Intrexon for the research and development costs. The agreement also provides for commercial and regulatory milestone payments to Intrexon, as well as a low double-digit percentage royalty based on the net sales from collaboration products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $47.54 USD +1.59

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $186.24 USD +1.02
Photon Technology International Inc $0.0001 USD 0.00
MorphoSys AG €65.32 EUR +0.56
XOMA Corp $3.86 USD +0.135
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.8x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 49.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.